Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Oct 17 2019

• By Joseph Haas

liver — Genfit should be the second company to file an NDA in NASH

Related Content

NASH Pipeline Includes Six Candidates That Have Reached Phase III

Oct 01 2019

Intercept’s Phase III Endpoints May Not Apply To Other Firms’ NASH Programs

May 25 2015

NASH Drugs Soon May Have A Registrational Pathway, Finally

Mar 30 2015

Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

Jul 25 2016

Genfit Hopes To Make Case For First-Line Treatment In NASH

Apr 04 2019

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Sep 30 2019

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Dec 05 2018

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

Sep 22 2017

Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues

Sep 25 2017

Genfit Dives Into Uncertain Late-stage NASH Trial

Nov 17 2015

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Apr 11 2019

Related Companies

Genfit SA

Intercept Pharmaceuticals, Inc.

Allergan plc

Eli Lilly and Company

Additional Topics

Business Strategies Clinical Trials Commercial Liver & Hepatic BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window